Treatment of acute pelvic infections with alphacillin (pivampicillin Hcl).
Fifty patients with acute pelvic inflammatory disease were treated with Alphacillin (Pivampicillin Hcl). The total daily dose consisted of 1050mg, given in three divided doses. Treatment was continued for six days. Full bacteriological investigations were performed. Therapy was continued so long as the condition of the patient improved. In case of failure change to other antibiotics or surgery were considered. The clinical response to Alphacillin was considered successful in 92% of patients. A significant observation in the trial was the low rate of residual pelvic pathology especially in patients with Acute/Chronic pelvic infection. The drug was found to be free from complications or any serious side effects. Mild epigastric discomfort was noticed in only 3 patients.
D000208:Acute Disease; D000667:Ampicillin / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000382:microbiology; D010917:Pivampicillin / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D012008:Recurrence
D010917:Pivampicillin; D000667:Ampicillin